Skip to Main Navigation
Skip to Page Content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Share This:
https://ntp.niehs.nih.gov/go/3268

TDMS Study 05099-99 Pathology Tables


                                     INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)
                                                      SALICYLAZOSULFAPYRIDINE


NTP Experiment-Test: 05099-99                                                                                     Report: PEIRPT03
Study Type: CHRONIC                                                                                               Date: 05/04/95
Route: GAVAGE                                                                                                     Time: 14:45:44


                                               05099/08 -VS- 05099/10 COMPARISON


       Facility:  SOUTHERN RESEARCH INSTITUTE

       Chemical CAS #:  599-79-1

       Lock Date:  04/19/94

       Cage Range:  All

       Reasons For Removal:    25018 Dosing Accident                   25019 Moribund Sacrifice
                               25020 Natural Death                     25017 Scheduled Sacrifice
                               25021 Terminal Sacrifice

       Removal Date Range:     All

       Treatment Groups:       Include 001    0 MG/KG
                               Include 004    RTD     0 MG/KG




























a  Number of animals examined microscopically at site and number of animals with lesion

                                                             Page   1

NTP Experiment-Test: 05099-99         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03
Study Type: CHRONIC                                      SALICYLAZOSULFAPYRIDINE                                  Date: 05/04/95  
Route: GAVAGE                                                                                                     Time: 14:45:44  
____________________________________________________________________________________________________________________________________

         B6C3F1 MICE MALE                          0 MG/KG      RTD                                                                 
                                                                0 MG/KG                                                             
____________________________________________________________________________________________________________________________________

DISPOSITION SUMMARY                                                                                                                 

  Animals Initially In Study                          60          110                                                               

  Scheduled Sacrifice                                              42                                                               
  Early Deaths                                                                                                                      
    Moribund Sacrifice                                 5            6                                                               
    Natural Death                                      3            4                                                               
    Dosing Accident                                    2                                                                            
  Survivors                                                                                                                         
    Terminal Sacrifice                                40                                                                            

  Animals Examined Microscopically                    50           52                                                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Esophagus                                          (50)         (52)                                                             
      Hemorrhage                                       1 (2%)                                                                       
   Intestine Large, Cecum                             (47)         (51)                                                             
      Parasite Metazoan                                1 (2%)                                                                       
   Liver                                              (50)         (52)                                                             
      Angiectasis                                                   1 (2%)                                                          
      Basophilic Focus                                 1 (2%)       2 (4%)                                                          
      Clear Cell Focus                                 2 (4%)       1 (2%)                                                          
      Eosinophilic Focus                               5 (10%)      5 (10%)                                                         
      Eosinophilic Focus, Multiple                     1 (2%)                                                                       
      Fatty Change, Focal                              1 (2%)                                                                       
      Hematopoietic Cell Proliferation                              1 (2%)                                                          
      Hemorrhage                                       1 (2%)       1 (2%)                                                          
      Inflammation, Subacute                           3 (6%)                                                                       
      Mineralization                                   2 (4%)                                                                       
      Mixed Cell Focus                                 2 (4%)                                                                       
      Necrosis                                         3 (6%)       2 (4%)                                                          
      Pigmentation, Bile                               1 (2%)       1 (2%)                                                          
      Vacuolization Cytoplasmic                        3 (6%)       3 (6%)                                                          
      Bile Duct, Cyst                                  2 (4%)       1 (2%)                                                          
   Mesentery                                          (4)          (6)                                                              
      Fat, Mineralization                                           1 (17%)                                                         
      Fat, Necrosis                                    3 (75%)      4 (67%)                                                         
   Pancreas                                           (50)         (52)                                                             
      Inflammation, Subacute                                        1 (2%)                                                          
      Acinus, Depletion Secretory                      1 (2%)                                                                       
      Duct, Cyst                                                    1 (2%)                                                          
   Stomach, Forestomach                               (50)         (52)                                                             
      Edema                                            1 (2%)                                                                       
      Foreign Body                                                  1 (2%)                                                          
      Hyperplasia                                     18 (36%)     27 (52%)                                                         

a  Number of animals examined microscopically at site and number of animals with lesion                                             

                                                             Page    2                                                              
NTP Experiment-Test: 05099-99         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03
Study Type: CHRONIC                                      SALICYLAZOSULFAPYRIDINE                                  Date: 05/04/95  
Route: GAVAGE                                                                                                     Time: 14:45:44  
____________________________________________________________________________________________________________________________________

         B6C3F1 MICE MALE                          0 MG/KG      RTD                                                                 
                                                                0 MG/KG                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
ALIMENTARY SYSTEM - CONT                                                                                                            
      Inflammation, Subacute                           4 (8%)      12 (23%)                                                         
      Ulcer                                            3 (6%)       2 (4%)                                                          
   Stomach, Glandular                                 (50)         (52)                                                             
      Erosion                                                       1 (2%)                                                          
      Hyperplasia                                      1 (2%)                                                                       
      Mineralization                                   1 (2%)                                                                       
      Pigmentation                                     1 (2%)                                                                       
      Ulcer                                            1 (2%)                                                                       
   Tooth                                                           (1)                                                              
      Developmental Malformation                                    1 (100%)                                                        
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   Blood Vessel                                       (50)         (52)                                                             
      Polyarteritis                                                 1 (2%)                                                          
   Heart                                              (50)         (52)                                                             
      Embolus                                          1 (2%)                                                                       
      Mineralization                                   1 (2%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Adrenal Cortex                                     (50)         (52)                                                             
      Accessory Adrenal Cortical Nodule                             1 (2%)                                                          
      Embolus                                          1 (2%)                                                                       
      Hyperplasia                                      8 (16%)                                                                      
      Hypertrophy                                     11 (22%)      8 (15%)                                                         
      Vacuolization Cytoplasmic                        1 (2%)                                                                       
      Capsule, Hyperplasia                             1 (2%)                                                                       
      Spindle Cell, Hyperplasia                                     1 (2%)                                                          
   Adrenal Medulla                                    (50)         (52)                                                             
      Embolus                                          1 (2%)                                                                       
   Islets, Pancreatic                                 (50)         (52)                                                             
      Embolus                                          1 (2%)                                                                       
      Hyperplasia                                      2 (4%)       3 (6%)                                                          
   Parathyroid Gland                                  (48)         (48)                                                             
      Cyst                                                          2 (4%)                                                          
   Pituitary Gland                                    (44)         (48)                                                             
      Pars Distalis, Cyst                                           1 (2%)                                                          
      Pars Distalis, Hyperplasia                                    2 (4%)                                                          
   Thyroid Gland                                      (50)         (52)                                                             
      Follicle, Cyst                                   6 (12%)      2 (4%)                                                          
      Follicle, Degeneration                           3 (6%)       5 (10%)                                                         
      Follicular Cell, Hyperplasia                     9 (18%)                                                                      
____________________________________________________________________________________________________________________________________

a  Number of animals examined microscopically at site and number of animals with lesion                                             

                                                             Page    3                                                              
NTP Experiment-Test: 05099-99         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03
Study Type: CHRONIC                                      SALICYLAZOSULFAPYRIDINE                                  Date: 05/04/95  
Route: GAVAGE                                                                                                     Time: 14:45:44  
____________________________________________________________________________________________________________________________________

         B6C3F1 MICE MALE                          0 MG/KG      RTD                                                                 
                                                                0 MG/KG                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Coagulating Gland                                  (5)                                                                           
      Dilatation                                       5 (100%)                                                                     
   Epididymis                                         (50)         (52)                                                             
      Congestion                                       1 (2%)                                                                       
      Granuloma Sperm                                  1 (2%)                                                                       
      Inflammation, Chronic                            1 (2%)                                                                       
      Mineralization                                                1 (2%)                                                          
   Preputial Gland                                    (49)         (51)                                                             
      Congestion                                       1 (2%)                                                                       
      Inflammation, Subacute                           2 (4%)       1 (2%)                                                          
      Duct, Cyst                                      45 (92%)     44 (86%)                                                         
   Prostate                                           (50)         (52)                                                             
      Cyst                                             1 (2%)                                                                       
      Hyperplasia                                      1 (2%)                                                                       
      Inflammation, Suppurative                        1 (2%)                                                                       
   Seminal Vesicle                                    (50)         (52)                                                             
      Atrophy                                          2 (4%)                                                                       
      Dilatation                                      14 (28%)      1 (2%)                                                          
      Infiltration Cellular, Mast Cell                              1 (2%)                                                          
      Inflammation, Chronic                            1 (2%)                                                                       
   Testes                                             (50)         (52)                                                             
      Mineralization                                   1 (2%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Bone Marrow                                        (50)         (52)                                                             
      Myeloid Cell, Hyperplasia                        2 (4%)                                                                       
   Lymph Node                                         (3)          (4)                                                              
      Bronchial, Hyperplasia, Lymphoid                              1 (25%)                                                         
      Inguinal, Hyperplasia, Lymphoid                  1 (33%)                                                                      
   Lymph Node, Mesenteric                             (50)         (52)                                                             
      Angiectasis                                     17 (34%)     20 (38%)                                                         
      Edema                                                         1 (2%)                                                          
      Hyperplasia, Lymphoid                            4 (8%)       5 (10%)                                                         
      Necrosis                                                      1 (2%)                                                          
   Spleen                                             (50)         (52)                                                             
      Angiectasis                                                   1 (2%)                                                          
      Atrophy                                          5 (10%)      2 (4%)                                                          
      Congestion                                       1 (2%)       1 (2%)                                                          

a  Number of animals examined microscopically at site and number of animals with lesion                                             

                                                             Page    4                                                              
NTP Experiment-Test: 05099-99         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03
Study Type: CHRONIC                                      SALICYLAZOSULFAPYRIDINE                                  Date: 05/04/95  
Route: GAVAGE                                                                                                     Time: 14:45:44  
____________________________________________________________________________________________________________________________________

         B6C3F1 MICE MALE                          0 MG/KG      RTD                                                                 
                                                                0 MG/KG                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
HEMATOPOIETIC SYSTEM - CONT                                                                                                         
      Depletion Cellular                                            1 (2%)                                                          
      Hematopoietic Cell Proliferation                11 (22%)      6 (12%)                                                         
      Hyperplasia, Lymphoid                            5 (10%)      9 (17%)                                                         
      Pigmentation, Hemosiderin                        2 (4%)                                                                       
   Thymus                                             (45)         (51)                                                             
      Atrophy                                          3 (7%)       2 (4%)                                                          
      Cyst                                             2 (4%)       1 (2%)                                                          
      Necrosis                                                      1 (2%)                                                          
      Thymocyte, Necrosis                              1 (2%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Skin                                               (50)         (52)                                                             
      Subcutaneous Tissue, Inflammation, Chronic       1 (2%)                                                                       
      Subcutaneous Tissue, Mineralization              1 (2%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   Bone                                               (50)         (52)                                                             
      Cranium, Hyperostosis                            2 (4%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   Brain                                              (50)         (52)                                                             
      Compression                                      1 (2%)                                                                       
      Embolus                                          1 (2%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (50)         (52)                                                             
      Alveolar Epithelium, Hyperplasia                 4 (8%)       3 (6%)                                                          
      Alveolus, Foreign Body                           1 (2%)                                                                       
      Alveolus, Hemorrhage                             1 (2%)                                                                       
      Alveolus, Infiltration Cellular, Histiocyte      3 (6%)                                                                       
      Mediastinum, Hemorrhage                          1 (2%)                                                                       
   Nose                                               (50)         (52)                                                             
      Glands, Cyst                                     1 (2%)                                                                       
      Glands, Mineralization                                        3 (6%)                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    

a  Number of animals examined microscopically at site and number of animals with lesion                                             

                                                             Page    5                                                              
NTP Experiment-Test: 05099-99         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03
Study Type: CHRONIC                                      SALICYLAZOSULFAPYRIDINE                                  Date: 05/04/95  
Route: GAVAGE                                                                                                     Time: 14:45:44  
____________________________________________________________________________________________________________________________________

         B6C3F1 MICE MALE                          0 MG/KG      RTD                                                                 
                                                                0 MG/KG                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   Ear                                                (1)          (1)                                                              
      External Ear, Inflammation, Granulomatous                     1 (100%)                                                        
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (50)         (52)                                                             
      Bacterium                                        1 (2%)                                                                       
      Fibrosis                                         1 (2%)                                                                       
      Glomerulosclerosis                               3 (6%)                                                                       
      Infarct                                                       5 (10%)                                                         
      Infiltration Cellular, Lymphocyte                1 (2%)                                                                       
      Inflammation, Chronic                                         1 (2%)                                                          
      Inflammation, Subacute                           2 (4%)       1 (2%)                                                          
      Mineralization                                  37 (74%)     49 (94%)                                                         
      Cortex, Cyst                                     5 (10%)      1 (2%)                                                          
      Cortex, Medulla, Inflammation, Suppurative       1 (2%)                                                                       
      Pelvis, Necrosis                                 1 (2%)                                                                       
      Renal Tubule, Casts                             13 (26%)     13 (25%)                                                         
      Renal Tubule, Degeneration                       3 (6%)       1 (2%)                                                          
      Renal Tubule, Regeneration                      38 (76%)     36 (69%)                                                         
      Transitional Epithelium, Hyperplasia             1 (2%)                                                                       
   Urinary Bladder                                    (50)         (52)                                                             
      Dilatation                                       1 (2%)                                                                       
      Inflammation, Subacute                           1 (2%)                                                                       
      Transitional Epithelium, Hyperplasia             1 (2%)                                                                       
                                                                                                                                    

a  Number of animals examined microscopically at site and number of animals with lesion                                             

                                                             Page    6                                                              
                             ------------------------------------------------------------                                           
                             ----------              END OF REPORT             ----------                                           
                             ------------------------------------------------------------